WORLDSymposium Connections Attendee Sign up
Registration is now open and is required for this unique, career-changing opportunity. Sign up to connect with a preferred mentor, in order of preference. Up to 3 mentors may be selected, though only one mentor will be assigned to each mentee. Each mentor will be assigned up to two mentees.
Upon registration, attendees will receive a confirmation email. Mentees will meet with assigned mentors just prior to the Be the Catalyst event on Sunday, January 31, 2027. Final details on this event will be provided in mid January 2027.
Mentor List
Heather Adams, PhD
Dr. Adams has been the neuropsychologist for the University of Rochester Batten Center since 2003, and is also a child psychologist. Her research in the NCLs and other neuronopathic conditions of childhood is centered on characterizing the neurocognitive phenotype and natural history of neurocognitive and other functional outcomes, including evaluation of cognition, adaptive function, mood and behavior, and psychosocial and quality of life impacts on affected individuals and families. Dr. Adams is a Lead Neuropsychologist for the recently funded Batten Disease Rare Disease Clinical Research Consortium (BD-CRC), a NIH-funded Rare Disease Clinical Research Network (RDCRN) Research Group.
Kimberly Angel
Kim Angel is Executive Director of the International MPS Network (IMPSN), where she leads global efforts to strengthen patient advocacy, advance equitable access to diagnosis, treatment and care, and improve outcomes for individuals and families affected by mucopolysaccharidoses (MPS) and related lysosomal storage disorders. Building on her previous leadership as Executive Director of the Canadian MPS Society, Kim works collaboratively with patient organizations, clinicians, researchers and industry partners to amplify the patient voice, address disparities in care, and drive meaningful progress for the global MPS community.
Danielle Dong, ScM, CGC
Danielle is the Global Medical Scientific Advocacy Lead, Rare Disease at Sanofi. She focuses on multistakeholder engagement and advocates for sustainable solutions in the generation and interpretation of rare disease evidence. She is the co-chair of the Patient Centered Outcomes Research Institute (PCORI) Rare Disease Advisory Panel. She previously worked in both US and global operations of the LSD Registries at Genzyme and Sanofi. Danielle is a certified genetic counselor with clinical and research experience.
N. Matthew Ellinwood, DVM, PhD
N. Matthew Ellinwood, DVM, PhD, trained in physiology and veterinary medicine at Colorado State University, followed by post-doctoral training in veterinary medical genetics, comparative medicine, and gene therapy at the University of Pennsylvania and the University of Nantes. He is Professor Emeritus at Iowa State University, where he focused on the MPS I and IIIB dog models. His research extended to multiple therapeutic approaches in numerous models, including MPS I, IIIA, IIIB, IIID, VI, and VII. He has served as CSO with the National MPS Society, Inc, and now consults on rare disease and newborn screening issues with Connetics Consulting LLC, where he draws on his varied research and advocacy experience to advance benefit to rare families.
Maria Fuller, PhD
Maria Fuller is a Clinical Scientist specialising in biochemical genetics and leads the National Referral Laboratory providing specialised diagnostic services for lysosomal disorders in Australia. Her research focuses on improving the efficiency, accuracy, and accessibility of laboratory diagnosis for lysosomal disorders through the development and translation of biomarkers into routine clinical practice. Maria contributes to laboratory quality and regulatory science, including the implementation of ISO 15189 standards and the advancement of biomarker qualification to support therapeutic development, regulatory approval and screening programs for lysosomal disorders. She is a Fellow of the Faculty of Science of the Royal College of Pathologists of Australasia and a Professor at Adelaide University, where she is a research leader at the Robinson Research Institute. Alongside her research and diagnostic role, Maria is committed to teaching and mentoring, and enjoys supervising postgraduate students, to foster the next generation of scientific leaders.
Roberto Giugliani, MD, PhD
Roberto Giugliani, Full Professor of Genetics at the Federal University of Rio Grande do Sul, in Brazil, is a medical geneticist who founded the Medical Genetics Service of Hospital de Clinicas of Porto Alegre, co-founded and currently leads "Casa dos Raros" (rare disease center), and leads the Brazilian Institute of Multiomics Applied to Precision Health. He is also the current President of the Latin American Society of Inborn Errors of Metabolism and Neonatal Screening, Editor-in-Chief of the Journal of Inborn Errors of Metabolism and Screening, and Member of the Brazilian Academy of Sciences.
Ozlem Goker-Alpan, M.D
Özlem Goker-Alpan is the Founder and President of the LDRTC, a non-profit clinical research organization in Fairfax, Virginia. Since 2012, she has led LDRTC as a premier center advancing therapies, accelerating early diagnosis, and fostering global collaboration in lysosomal and rare diseases. Internationally recognized for her expertise in Gaucher and related disorders, Dr. Goker-Alpan drives biomarker discovery, immune-mechanism research, and clinical trial development, while mentoring future leaders in rare disease medicine.
Natalia Gomez-Ospina, MD, PhD
Dr. Gómez-Ospina is an Assistant Professor at Stanford University and a Medical Geneticist. Her research focuses on using hematopoietic transplantation to deliver proteins to the central nervous system and on developing a platform for treating enzyme deficiencies. She has led groundbreaking preclinical studies on genome-edited cells for Mucopolysaccharidosis type I, Gaucher disease, and Progranulin deficiency. She has published in top journals and received numerous awards, including the Genetics and Genomics Medicine Innovation Award from ACMG.
Kristina An Haack, MD
Dr. An Haack has been a healthcare industry professional for over 10 years. She is currently the Head of Rare Neurometabolic Disease Clinical Development, part of the RARE Therapeutic Area in Sanofi’s R&D organization. She is a pediatrician by training and specialized in Inherited Metabolic Disorders with focus on neurometabolic orphan diseases. Dr. An Haack has over 25 years’ experience in Academia, Research, Drug Development and Project Direction, and is the Medical Leader of Sanofi’s Pediatric Medicines Network.
Nadene D. Henderson, MS, LCGC
Nadene began working in LSDs in 1994, and has over 32 years working in rare diseases. Her career involves both clinical and research care for families impacted by these conditions. She was part of the FDA-approval for fifteen different therapies for LSDs (plus hypophosphatasia), a 2024 Sanofi TORCH awardee, and received the University of Pittsburgh Chancellor’s Distinguished Service Awards (Mentor category) in 2026. Nadene's current focus is study coordination including gene therapy, investigational products, registries, as well as newborn screening and training future health care professionals.
Priya Kishnani, MD
Priya Kishnani is the Chen Family Distinguished Professor of Pediatrics, Division of Medical Genetics chief, and professor in the Department of Molecular Genetics and Microbiology at Duke University.
Dr. Kishnani has conducted groundbreaking clinical and translational research in the fields of lysosomal diseases and glycogen storage diseases. Kishnani has been instrumental in the development of alglucosidase alfa as the first FDA approved therapy for Pompe disease and also in clinical trial design for next gen ERT's, substrate reduction therapy and gene therapy for several lysosomal and glycogen storage diseases. She has shown commitment to understanding the natural history and development of management guidelines of several LDs and GSDs. Kishnani is actively involved in research surrounding the role of immune response including immune modulation strategies for several lysosomal diseases. Kishnani is also involved in biomarker discovery, and the role of biomarkers in diagnosis and monitoring of individuals with rare diseases.
Terri L. Klein, MPA
Terri Klein, MPA, is the President and Chief Executive Officer of the Nation MPS Society. Terri has 14 years of experience in rare diseases, including her work with the Society for nine years, serving as Development Director and Director of Operations. Terri has a direct, personal connection and history with MPS and ML. Her daughter, Jennifer, has ML III. She has been involved as a parent and staff member on all fronts in the fight for a cure. Her family has worked for years, advocating for MPS and ML through the Society.
Francyne Kubaski, MSc, PhD
Francyne Kubaski, MSc, PhD, is a Staff Scientist at the Biochemical Genetics Laboratory of the Greenwood Genetic Center in South Carolina. Her research focuses on developing advanced diagnostic methods for inborn errors of metabolism, emphasizing lysosomal disorders and tandem mass spectrometry. Dr. Kubaski is also interested in biomarker studies to enhance diagnosis, prognosis, and therapeutic monitoring, advancing translational research in rare disease and contributing to newborn screening and early detection efforts in metabolic medicine.
Malte Lenders, PhD
Professor Malte Lenders (PhD) studied Biology at the University of Muenster, Germany focusing on genetics and biotechnology. Since taking up his position in 2011 as laboratory head under Prof. Eva Brand at the University Hospital of Münster, he has been jointly responsible for research projects that have resulted in more than 50 peer-reviewed publications on Fabry disease. His research focuses on inflammation, immunogenicity, and the mechanisms of various therapeutic approaches for treating Fabry disease.
Marc C. Patterson, MD
Dr. Patterson has more than 40 years in academic medicine, focusing on rare neurometabolic disease diseases, particularly lysosomal diseases and congenital disorders of glycosylation. Retired from practice at the Mayo Clinic in December 2024, Dr. Patterson then joined IntraBio as CMO on January 1, 2025.
Carlos E. Prada, MD
Dr. Prada is the Chair of the Edwards Family Division of Genetics & Rare Diseases at Lurie Children's Hospital and Northwestern University.
Dr. Prada has been the principal investigator on numerous federal and foundation grants, including grants from the Department of Defense and National Institute of Neurological Disorders and Stroke. He is principal investigator for several gene therapy studies focus on lysosomal storage disorders.
Uma Ramaswami, FRCPCH, MD
Dr. Ramaswami is a full-time metabolic clinician with an active translational research portfolio. She is passionate in caring for patients with rare diseases, with a unique perspective of having experience in both paediatric and adult-onset rare diseases. She is interested in promoting patient-reported outcomes for both clinical management and research outcomes. Outside her day job, she actively engages in carbon offset initiatives in her hometown and is a referee coach for touch football.
Raphael Schiffmann, MD, MHSc
Dr. Schiffmann is an expert on neurometabolic diseases. He currently is a Professor in the Department of Internal Medicine, Texas Christian University.
Dr. Schiffmann has been performing pre-clinical and clinical research on lysosomal diseases since 1991 with a special focus on the natural history, pathogenesis and therapy of Fabry disease, Gaucher disease and the leukodystrophies. He has published 299 peer-reviewed research articles and over 15 book chapters.
Bibliography: https://scholar.google.com/citations?user=ZRmqVIgAAAAJ&hl=en
Ellen Sidransky, MD
Dr. Ellen Sidransky, Branch Chief of the Medical Genetics Branch, is a pediatrician and geneticist in the NHGRI at NIH. She played a lead role in establishing the association between glucocerebrosidase and parkinsonism. Her work focuses on complexity in "simple" Mendelian disorders, lysosomal pathways in parkinsonism, and small molecule chaperone therapies for Gaucher and Parkinson diseases. She received the 2021 WORLDSymposium Roscoe O. Brady Award and the 2024 Breakthrough Prize in Life Sciences.
Danilo A. Tagle, PhD, MS
Danilo Tagle is Senior Scientific Advisor on Regulatory and Translational Research as a Special Volunteer at NCATS, NIH, after retiring as Director of the Office of Special Initiatives after more than 32 years of public service. He has led interdisciplinary programs advancing diagnostics and therapeutics for human diseases, collaborating with agencies like FDA, NASA, DARPA, and private industry. These programs include new approach methodologies (NAMs) including microphysiological systems; 3D bioprinting; automated chemistry; electronic nose technology; quantum technologies; and exosome analyses for biomarker and therapy development. Dan has served on advisory and review committees such as the Biological and Physical Sciences Federal Advisory Committee and LabCorp NAM Scientific Advisory Board. He holds a PhD and MS in molecular biology and genetics from Wayne State University, completed postdoctoral research in Human Genetics at the University of Michigan, and has received numerous awards, including several NIH Director’s Awards, the Roscoe O. Brady Award, the Henry J. Heimlich Award, the HHS Secretary's Award for RADx, NASA Silver Group Achievement Award, and the William and Eleanor Cave Award.
Raymond Y. Wang, MD
Dr. Raymond Wang is an NIH-funded clinical biochemical geneticist and lysosomal storage disorder specialist who also oversees clinical trials for gene therapy in lysosomal storage disorders (especially neurodegenerative), and a translational research laboratory studying somatic genome editing and other methods for unmet therapeutic needs in lysosomal storage disorders.
Melissa Wasserstein, MD
Melissa Wasserstein, MD, is the Chief of the Division of Pediatric Genetic Medicine at the Children’s Hospital at Montefiore and professor of Pediatrics and Genetics at the Albert Einstein College of Medicine. After graduating from Cornell University, she received her medical degree from New York University School of Medicine, followed by a pediatrics residency and medical genetics fellowship at Mount Sinai. A board-certified biochemical geneticist and pediatrician, Dr. Wasserstein diagnoses and manages patients with inborn errors of metabolism. Her research activities focus on expanding and enhancing newborn screening to optimize the outcome of infants with rare disorders.
David A. Weinstein, MD, MMsc
During his 30-year academic career, Dr. Weinstein focused on research and clinical care of patients with glycogen storage disease. After launching the world’s first gene therapy trial for GSD Ia, he joined industry and led the GM1 gangliosidosis and MLD gene therapy trials at Passage Bio. He subsequently served as acting CMO for Grace Science initiating the gene therapy trial for NGLY1 deficiency. He is presently a consultant for rare disease trials.
Ari Zimran, MD
Over three decades ago, Dr. Zimran founded the world’s largest Gaucher clinic, focusing on natural history, rare manifestations, and its association with Parkinson’s disease (PD). His team pioneered molecular diagnostics: PCR genotyping, PGD, and NIPT, and validated LysoGb1 as a key biomarker. He served as lead PI in trials leading to miglustat, velaglucerase-alfa, and taliglucerase-alfa approvals. More recently, he founded AGYANY Pharma to advance high-dose ambroxol and novel chaperones for Gaucher and GBA1-related PD (Sidransky syndrome).
*All WORLDSymposium Connections participants must be registered for and attend WORLDSymposium 2027 in-person to participate.
